LivaNova PLC has announced it received CE Mark for its Vagus Nerve Stimulation Therapy (“VNS Therapy”) System comprised of the SenTiva generator and next-generation Programming System for the treatment of patients with drug-resistant epilepsy (“DRE”). The Company received FDA approval for the full VNS Therapy System in October 2017. The SenTiva generator offers the smallest and lightest responsive therapy with a ...

LivaNova has won FDA approvals for its newest vagus nerve stimulation system for treating epilepsy in patients as young as four years old. The system, which includes the SenTiva implantable neurostimulator and the VNS Therapy Programming system, monitors brain activity and delivers therapy when it believes a seizure may be imminent. During therapy it continues its monitoring routine, increasing its stimulation if it detects its initial attempts f...

LivaNova PLC has announced that its latest VNS Therapy systems (“VNS Therapy”) received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This FDA approval ensures VNS Therapy patients with the latest technology may visit any MRI center in the U.S. and have access to more than 90% of scans routinely performed on patients with epilepsy.